Download PDF
Klin Monbl Augenheilkd 2011; 228(1): R1-R13
DOI: 10.1055/s-0030-1250754
KliMo-Refresher
Rubrikherausgeber: G. Duncker, Halle, C. Meltendorf, Halle
© Georg Thieme Verlag KG Stuttgart · New York

Klinik und Therapie des diabetischen Makulaödems

G. E. Lang1 , S. J. Lang2
  • 1Universitäts-Augenklinik Ulm, Ulm
  • 2Universitäts-Augenklinik Freiburg, Freiburg
Further Information

Publication History

Publication Date:
19 January 2011 (online)

Also available at
    Permissions and Reprints

Einleitung

Die diabetische Retinopathie ist die häufigste Folgeerkrankung des Diabetes mellitus. Es kommt zu einer progredienten Schädigung der Netzhaut im Sinne einer Mikroangiopathie. In Industrieländern ist die diabetische Retinopathie trotz aller Bemühungen noch immer die häufigste Ursache für erhebliche Sehbehinderung oder Erblindung im Erwachsenenalter.

Literatur

  • 1 Lang G E. Diabetische Retinopathie – Stadieneinteilung und Laserbehandlung.  Klin Monatsbl Augenheilkd. 2005;  222 R1-R18
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Klein R. The Epidemiology of diabetic Retinopathy.. In: Duh E Diabetic Retinopathy.. Humana Press; 2008: 67-107
    CrossrefGoogle Scholar
  • 3 Kempen J H, O'Calmain B J, Leske M C et al. The prevalence of diabetic retinopathy among adults in the United States.  Arch Ophthalmol. 2004;  122 552-563
    CrossrefPubMedGoogle Scholar
  • 4 Klein R, Klein B E, Moss S E et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years.  Arch Ophthalmol. 1984;  102 520-526
    CrossrefPubMedGoogle Scholar
  • 5 Klein R, Klein B E, Moss S E et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years.  Arch Ophthalmol. 1984;  102 527-532
    CrossrefPubMedGoogle Scholar
  • 6 Hirai F E, Knudtson M D, Klein B E et al. Clinically significant macular edema and survival in type 1 and type 2 diabetes.  Am J Ophthalmol. 2008;  145 700-706
    CrossrefPubMedGoogle Scholar
  • 7 Klein R, Knudtson M D, Lee K E et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXIII. The twenty-five-year incidence of macular edema in persons with type 1 diabetes.  Ophthalmology. 2009;  116 497-503
    CrossrefPubMedGoogle Scholar
  • 8 Swenarchuk L E, Whetter E, Adamis A P. The Role of Inflammation in the Pathophysiology of diabetic Retinopathy.. In: Duh E Diabetic Retinopathy.. Humana Press; 2008: 303-332
    Google Scholar
  • 9 Caldwell R B, Bartoli M, Behzadian M A et al. Vascular endothelial growth factor and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives.  Diabetes Metab Res Rev. 2003;  19 442-445
    CrossrefPubMedGoogle Scholar
  • 10 Lang G E. Optical coherence tomography findings in diabetic retinopathy.  Dev Ophthalmol. 2007;  39 31-47
    PubMedGoogle Scholar
  • 11 Joussen A M, Smyth N, Niessen C. Pathophysiology of diabetic macular edema.  Dev Ophthalmol. 2007;  39 1-12
    PubMedGoogle Scholar
  • 12 Deissler H, Lang G E. Wirkung von VEGF165 und dem VEGF-Aptamer Pegaptanib (Macugen®) auf die Zusammensetzung der Tight Junctions mikrovaskulärer Endothelzellen der Retina.  Klin Monatsbl Augenheilk. 2008;  225 863-867
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Lang G E. Laser treatment of diabetic retinopathy.  Dev Ophthalmol. 2007;  39 48-68
    PubMedGoogle Scholar
  • 14 Early Treatment Diabetic Retinopathy Study Group . Photocoagulation for diabetic macular edema. ETDRS report no 1.  Arch Ophthalmol. 1985;  91 1795-1806
    PubMedGoogle Scholar
  • 15 Diabetic Retinopathy Clinical Research Network . A randomized trial comparing intravitreal triamcinolone acteonide and focal/grid photocoagulation in diabetic macular edema.  Ophthalmology. 2008;  115 1447-1450
    CrossrefPubMedGoogle Scholar
  • 16 Diabetic Retinopathy Clinical Research Network . Comparison of modified-ETDRS and mild macular grid laser photocoagulation strategies for diabetic macular edema.  Arch Ophthalmol. 2007;  125 469-480
    CrossrefPubMedGoogle Scholar
  • 17 Diabetic Retinopathy Study Group . Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of diabetic retinopathy study findings. DRS report no 8.  Ophthalmology. 1981;  88 583
    PubMedGoogle Scholar
  • 18 Scott I U, Danis R P, Bressler S B et al. for the DRCRnetwork.. Effekt of focal/grid photocoagulation on visual acuity and retinal thickening in eyes with non-center involved clinically significant diabetic macular edema.  Retina. 2009;  29 613-617
    CrossrefPubMedGoogle Scholar
  • 19 Diabetic Retinopathy Clinical Research Network . Three year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitral triamcinolone for diabetic macular edema.  Arch Ophthalmol. 2009;  127 245-251
    CrossrefPubMedGoogle Scholar
  • 20 Gandorfer A. Diffuse diabetic macular edema: pathology and implications for surgery.  Dev Ophthalmol. 2007;  39 88-95
    PubMedGoogle Scholar
  • 21 Joussen A M. Benefits and limitations in vitreoretinal surgery for proliferative diabetic retinopathy and macular edema.  Dev Ophthalmol. 2007;  39 69-87
    PubMedGoogle Scholar
  • 22 Jonas J B. Intravitreal triamcinolone acetonide for diabetic retinopathy.  Dev Ophthalmol. 2007;  39 96-110
    PubMedGoogle Scholar
  • 23 Gerding H, Hefner L, Riese J et al. Fokale Laserkoagulation des diabetischen Makulaödems nach vorbereitender Triamcinolon-Injektion: Ergebnisse nach 6 Monaten.  Klin Monatsbl Augenheilkd. 2010;  227 249-251
    Article in Thieme ConnectPubMedGoogle Scholar
  • 24 Pearson P Fluocinolone Acetonide Implant Study Group et al. Fluocinolone acetonide intravitreal implant to treat diabetic macular edema.  Invest Ophthalmol Vis Sci. 2006;  47 E-Abstract 5442
    PubMedGoogle Scholar
  • 25 Champochiaro P A, Hafiz G, Shah S M Famous Study Group et al. Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert.  Ophthalmology. 2010;  117 1393-1399
    CrossrefPubMedGoogle Scholar
  • 26 Do D V, Haller J A et al. Anti-VEGF Therapy as emerging Treatment for diabetic Retinopathy.. In: Duh E Diabetic Retinopathy.. Humana Press; 2008: 401-421
    Google Scholar
  • 27 Kakkassery V, Winterhalter S, Joussen A M. Die Rolle der Anti-VEGF-Therapie in der Behandlung des diabetischen Makulaödems.  Klin Mbl Augenheilkd. 2010;  227 701-711
    PubMedGoogle Scholar
  • 28 Ferrara N. Vascular endothelial growth factor: Basic Science and Clinical Progress.  Endocrine Reviews. 2004;  25 581-611
    CrossrefPubMedGoogle Scholar
  • 29 Starita C, Patel M, Katz B et al. Vascular endothelial growth factor and the potential therapeutic use of pegaptanib (Macugen) in diabetic retinopathy.  Dev Ophthalmol. 2007;  39 122-148
    PubMedGoogle Scholar
  • 30 Deissler H L, Lang G E. In vitro-Untersuchungen zum Wirkungsmechanismus von VEGF und seinen Inhibitoren.  Klin Monatsbl Augenheilk. 2008;  225 623-628
    Article in Thieme ConnectPubMedGoogle Scholar
  • 31 Deissler H, Deissler H, Lang S et al. VEGF-induced effects on proliferation, migration and tight junctions are restored by ranibizumab (Lucentis®) in microvascular retinal endothelial cells.  Br J Ophthalmol. 2008;  92 839-843
    CrossrefPubMedGoogle Scholar
  • 32 Mendrinos E, Donati G, Pournaras C J. Rapid and persistent regression of severe new vessels on the disc in proliferative diabetic retinopathy after a single intravitreal injection of pegaptanib.  Acta Ophthalmol. 2009;  87 683-684
    CrossrefPubMedGoogle Scholar
  • 33 Cunningham Jr. E T, Adamis A P, Altaweel M Macugen Diabetic Study Group et al. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema.  Opthalmology. 2005;  112 1747-1757
    CrossrefPubMedGoogle Scholar
  • 34 Adamis A P, Altaweel M, Bressler N M Macugen Diabetic Retinopathy Study Group et al. Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals.  Ophthalmology. 2006;  113 23-28
    CrossrefPubMedGoogle Scholar
  • 35 Chun D W, Heier J S, Topping T M et al. A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema.  Ophthalmology. 2006;  113 1706-1712
    CrossrefPubMedGoogle Scholar
  • 36 Nguyen Q D, Shah S M, Khwaja A A et al. Two-year outcomes of the ranibizumab for edema of the macula in diabetes (READ-2) Study.  Ophthalmology. 2010;  117 2146-2151
    CrossrefPubMedGoogle Scholar
  • 37 Massin P, Bandello F, Garweg J G et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month randomized, controlled, double-masked, multicenter phase II study.  Diabetes Care. 2010;  33 2399-2405
    CrossrefPubMedGoogle Scholar
  • 38 Mitchell P et al. Efficacy and safety of intravitreal ranibizumab as adjunctive therapy to laser photocoagulation or as monotherapy in diabetic macular edema: 12-month results from the RESTORE study. Berlin; World Ophthalmology Congress 2010: Abstract WE-38-02
    Google Scholar
  • 39 The Diabetic Retinopathy Clinical Research Network . Randomized trial evaluation ranibizumab plus prompt or deferred laser or triamconolone plus prompt laser for diabetic macular edema.  Ophthalmology. 2010;  117 1064-1077
    CrossrefPubMedGoogle Scholar
  • 40 Isaacs T W, Barry C. Rapid resolution of severe disc new vessels in proliferative diabetic retinopathy following a single intravitreal injection of bevacizumab (Avastin).  Clin Experiment Ophthalmol. 2006;  34 802-803
    CrossrefPubMedGoogle Scholar
  • 41 Avery R L, Pearlman J, Pieramici D J et al. Intravitreal bevacizumab (Avastin®) in the treatment of proliferative diabetic retinopathy.  Ophthalmology. 2006;  113 1695.e1-e15
    PubMedGoogle Scholar
  • 42 Grisanti S, Biester S, Peters S Tuebingen Bevacizumab Study Group et al. Intracameral bevacizumab for iris rubeosis.  Am J Ophthalmol. 2006;  142 158-160
    CrossrefPubMedGoogle Scholar
  • 43 Chalam K V, Gupta S K, Grover S et al. Intracameral Avastin dramatically resolves iris neovascularization and reverses neovascular glaucoma.  Eur J Ophthalmol. 2008;  18 255-262
    PubMedGoogle Scholar
  • 44 Minnella A M, Savastano C M, Ziccardi L et al. Intravitreal bevacizumab (Avastin) in proliferative diabetic retinopathy.  Acta Ophthalmol. 2008;  86 683-687
    CrossrefPubMedGoogle Scholar
  • 45 Spaide R F, Fisher Y L. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage.  Retina. 2006;  26 275-278
    CrossrefPubMedGoogle Scholar
  • 46 Scott I U, Edwards A R, Beck R W Diabetic Retinopathy Clinical Research Network et al. A phase 2 randomized clinical trial of intravitreal bevacizumab for diabetic macular edema.  Ophthalmology. 2007;  114 1860-1867
    CrossrefPubMedGoogle Scholar
  • 47 Michaelides M, Kaines A, Hamilton R D et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2.  Ophthalmology. 2010;  117 1078-1086
    CrossrefPubMedGoogle Scholar

Prof. Dr. Gabriele E. Lang

Augenklinik
Universitätsklinikum Ulm

Prittwitzstraße 43

89075 Ulm

Email: sekretariat.augenklinik@uniklinik-ulm.de

      >